Arvinas Competitors and Similar CompaniesClear all
Arvinas's competitors and similar companies include Foghorn Therapeutics, Lyell and Agenus.
 Arvinas Arvinas is a biopharmaceutical company focused on developing protein degradation therapeutics for cancers and other diseases. |  Foghorn Therapeutics Foghorn Therapeutics is a developer of gene therapies for hematologic cancers and solid tumors. |  Agenus Agenus is a clinical-stage immuno-oncology company which focuses on the discovery and development of therapies that engage the body's immune system for patients suffering with cancer. | ||
Founding Date | Founding Date N/A | Founding Date 2016 | Founding Date 2018 | Founding Date 1994 |
Type | Type Public | Type Public | Type Public | Type Public |
Tags | ||||
Locations | Locations New Haven, US HQ | Locations Cambridge, US HQ Cambridge, US | Locations South San Francisco, US HQ Bothell, US Seattle, US | Locations Lexington, US HQ Cambridge, GB Berkeley, US New York, US |
Employees | Employees 13329% increase | Employees 16135% increase | Employees 188 | Employees 32812% increase |
Valuation ($) | Valuation ($) 1.2 b | Valuation ($) 179.4 m | Valuation ($) 435.7 m | Valuation ($) 296.5 m |
Twitter followers | Twitter followers 3.1 k | Twitter followers 1.1 k | Twitter followers N/A | Twitter followers 2.5 k |
Number of tweets (last 30 days) | Number of tweets (last 30 days) 13 | Number of tweets (last 30 days) 9 | Number of tweets (last 30 days) N/A | Number of tweets (last 30 days) 8 |
Average likes per tweet (last 30 days) | Average likes per tweet (last 30 days) 2 | Average likes per tweet (last 30 days) 2.3 | Average likes per tweet (last 30 days) N/A | Average likes per tweet (last 30 days) 13.4 |
Percentage of tweets with engagement (last 30 days) | Percentage of tweets with engagement (last 30 days) 84.62% | Percentage of tweets with engagement (last 30 days) 88.89% | Percentage of tweets with engagement (last 30 days) N/A | Percentage of tweets with engagement (last 30 days) 100% |
Employee Rating | Employee Rating 4.7 | Employee Rating 4.2 | Employee Rating 3.4 | Employee Rating 3.2 |
Financial | ||||
Revenue (est.) | Revenue (est.) $131.4m (FY, 2022) | Revenue (est.) $19.2m (FY, 2022) | Revenue (est.) $84.7m (FY, 2022) | Revenue (est.) $98m (FY, 2022) |
Net income | Net income ($282.5m) (FY, 2022) | Net income ($108.9m) (FY, 2022) | Net income ($183.1m) (FY, 2022) | Net income ($230.7m) (FY, 2022) |
Funding | ||||
Total funding raised | Total funding raised $ 111.6m | Total funding raised $ 50m | Total funding raised N/A | Total funding raised $ 171.1m |
For sources of this data, please see the company profile
View Company Profiles
Foghorn Therapeutics
HQ
Cambridge, US
Employees
161↑ 35% increase
Foghorn Therapeutics is a developer of gene therapies for hematologic cancers and solid tumors.
View company
Lyell
HQ
South San Francisco, US
Employees
188
Lyell Immunopharma is a T-cell reprogramming company to cure patients with solid tumors.
View companyAgenus
HQ
Lexington, US
Employees
328↑ 12% increase
Agenus is a clinical-stage immuno-oncology company which focuses on the discovery and development of therapies that engage the body's immune system for patients suffering with cancer.
View company